Immutrin secures £65m Series A for amyloid-removing heart therapy

The proceeds from this financing will fund Immutrin’s lead asset through clinical proof of concept in ATTR cardiomyopathy, a serious and often fatal form of amyloidosis. The oversubscribed round was led by Frazier Life Sciences, with participation from F-Prime, Qiming Venture Partners, SR One, Cambridge Innovation Capital and Cambridge Enterprise Ventures.

Amyloidosis is a group of rare, progressive diseases where misfolded transthyretin protein aggregates into amyloid fibrils, accumulating in tissues and causing irreversible organ damage, especially to the heart. While recent advances slow or suppress amyloid production, no approved therapies effectively clear pre-existing deposits – a step seen as crucial for restoring organ function. Immutrin’s lead antibody targets transthyretin-specific (ATTR) amyloidosis and selectively binds to amyloid fibrils, sparing native protein, and is engineered to deplete amyloid deposits in tissue via a targeted and coordinated immune response.

“Immutrin’s lead asset has the potential to clear large, established amyloid deposits more effectively than other depleter antibodies in development, while complementing therapies that suppress amyloid production,” explained Sef Kurstjens, Chair of the Board at Immutrin.

Immutrin was co-founded by Cambridge Innovation Capital, academic founders Professor Sir Mark Pepys FRS, Nobel Laureate Sir Gregory Winter FRS and Professor Daniel Christ.